Immunocore

Immunocore is an Oxfordshire-based worldwide commercial-stage biotechnology firm that investigates and develops biological therapeutics using soluble T-cell receptor technology. We are a commercial-stage T cell receptor biotechnology firm developing and commercializing a new generation of transformational medications to address unmet needs in cancer, infectious, and autoimmune diseases.

Immunocore pushes science by helping people. Its goal is to provide best-in-class biological medicines that have the potential to change the lives of individuals suffering from severe diseases such as cancer, infectious diseases, and autoimmune disorders.

Its primary therapeutic focus is oncology, where vital clinical studies for the main program, tebentafusp (IMCgp100), as a possible therapy for metastatic uveal melanoma, a rare form of eye cancer, is presently ongoing. In addition, it has a robust pipeline of initiatives spanning a wide range of cancer indications, as well as infectious and autoimmune diseases.

Founded: 1998
Headquarters: Oxford, England, UK
Website: https://www.immunocore.com/